DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Expert Opinion Hydroxyurea Could Prevent Strokes for People With Sickle Cell Disease in Lieu of Transfusions During COVID-19 Blood Supply Shortage
The COVID-19 pandemic threatens to cause a blood supply shortage in the United States, and as a result, clinicians may be compelled to ration or conserve blood products. For people living with sickle cell disease (SCD), blood transfusions are often necessary to decrease the frequency of severe symptoms.
In a new Blood paper, Michael R. DeBaun, MD, MPH, of Vanderbilt University Medical Center, Vanderbilt-Meharry Sickle Cell Disease Center of Excellence, suggests that while monthly blood transfusions are the standard method of stroke prevention for children with SCD and at high risk of strokes, initiation of hydroxyurea therapy may be an effective alternative, if the monthly blood transfusions are interrupted.
Related Content
-
videos & visualsYou Should Get a COVID-19 Vaccine – Portuguesehttps://www.youtube.com/watch?v=t8UywR9x...
-
education & researchFrequently Asked Questions About the COVID-19 VaccineWhy should I get vaccinated for COVID-19...
-
news & eventsCOVID-19 Outcomes Among Individuals With Sickle Cell Disease by IASCNAPA – WebinarLearning Objectives: • Understand how...
-
news & eventsGBT Supports Sickle Cell Patients During COVID-19 PandemicGlobal Blood Therapeutics (GBT) is takin...
-
news & eventsIn Support of Rare Disease Patients Impacted by COVID-19, NORD Launches Premium and Limited Medical Relief ProgramUnited with more than 25 million America...
-
videos & visualsSCDAA’s Response to the COVID-19 Pandemichttps://www.youtube.com/watch?v=ikKWJoFb...
-
news & eventsAccess the Care for Sickle Cell Disease Pre-Summit WebinarThe 14th Annual Sickle Cell Disease Rese...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.